Literature DB >> 24126730

Prostate cancer: radium-223: a new treatment option for bone-metastatic CRPC.

Petros D Grivas1, Evan T Keller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24126730     DOI： 10.1038/nrurol.2013.232

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice.

Authors:  Gjermund Henriksen; Darrell R Fisher; John C Roeske; Øyvind S Bruland; Roy H Larsen
Journal:  J Nucl Med       Date:  2003-02       Impact factor: 10.057

Review 2.  High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?

Authors:  Øyvind S Bruland; Sten Nilsson; Darrell R Fisher; Roy H Larsen
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

Review 3.  A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer.

Authors:  S Nilsson; P Strang; A K Aksnes; L Franzèn; P Olivier; A Pecking; J Staffurth; S Vasanthan; C Andersson; Ø S Bruland
Journal:  Eur J Cancer       Date:  2012-02-15       Impact factor: 9.162

Review 4.  Bone-seeking radionuclides for therapy.

Authors:  Val J Lewington
Journal:  J Nucl Med       Date:  2005-01       Impact factor: 10.057

5.  Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model.

Authors:  Gjermund Henriksen; Knut Breistøl; Øyvind S Bruland; Øystein Fodstad; Roy H Larsen
Journal:  Cancer Res       Date:  2002-06-01       Impact factor: 12.701

Review 6.  Alpharadin, a 223Ra-based alpha-particle-emitting pharmaceutical for the treatment of bone metastases in patients with cancer.

Authors:  Knut Liepe
Journal:  Curr Opin Investig Drugs       Date:  2009-12

Review 7.  Radium-223 for the treatment of prostate cancer.

Authors:  Shaista Hafeez; Christopher Parker
Journal:  Expert Opin Investig Drugs       Date:  2013-01-15       Impact factor: 6.206

8.  A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer.

Authors:  Christopher C Parker; Sarah Pascoe; Aleš Chodacki; Joe M O'Sullivan; Josep R Germá; Charles Gillies O'Bryan-Tear; Trond Haider; Peter Hoskin
Journal:  Eur Urol       Date:  2012-09-13       Impact factor: 20.096

9.  Alpha emitter radium-223 and survival in metastatic prostate cancer.

Authors:  C Parker; S Nilsson; D Heinrich; S I Helle; J M O'Sullivan; S D Fosså; A Chodacki; P Wiechno; J Logue; M Seke; A Widmark; D C Johannessen; P Hoskin; D Bottomley; N D James; A Solberg; I Syndikus; J Kliment; S Wedel; S Boehmer; M Dall'Oglio; L Franzén; R Coleman; N J Vogelzang; C G O'Bryan-Tear; K Staudacher; J Garcia-Vargas; M Shan; Ø S Bruland; O Sartor
Journal:  N Engl J Med       Date:  2013-07-18       Impact factor: 91.245

10.  Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.

Authors:  Sten Nilsson; Lars Franzén; Christopher Parker; Christopher Tyrrell; René Blom; Jan Tennvall; Bo Lennernäs; Ulf Petersson; Dag C Johannessen; Michael Sokal; Katharine Pigott; Jeffrey Yachnin; Michael Garkavij; Peter Strang; Johan Harmenberg; Bjørg Bolstad; Oyvind S Bruland
Journal:  Lancet Oncol       Date:  2007-07       Impact factor: 41.316
  10 in total
  1 in total

Review 1.  PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What's Now, What's New, and What's Coming?

Authors:  Andrea Marchetti; Matteo Rosellini; Giacomo Nuvola; Elisa Tassinari; Veronica Mollica; Alessandro Rizzo; Matteo Santoni; Alessia Cimadamore; Andrea Farolfi; Rodolfo Montironi; Stefano Fanti; Francesco Massari
Journal:  Cancers (Basel)       Date:  2022-02-11       Impact factor: 6.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.